Acutus Medical Locks In $26.2 Million Series B Financing
SAN DIEGO, Sept. 30, 2014 /PRNewswire/ --
Acutus Medical, Inc. (ACM), a medical device company developing a minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system to identify the sources that cause and / or sustain complex cardiac arrhythmias, including atrial fibrillation, announced it has completed an additional $26.2M financing to continue developing its imaging/mapping system as well as bring to market a complete product portfolio. The financing will allow Acutus Medical to complete work on the AcQMapTM High Resolution, Imaging and Mapping System and broaden their product portfolio to include diagnostic catheters, therapeutic catheters and additional new innovative therapeutic products. Acutus Medical will also be collaborating with Boise State University to develop a next generation therapeutic technology. The expansion of the portfolio to include everything needed to diagnose and treat all EP patients puts Acutus Medical in a position to be a complete, stand-alone business.
"We are pleased to be working with top tier investors that share our passion to develop the AcQMap System but understand the importance of offering a complete portfolio of products to help physicians tailor patient treatment while being respectful of the financial pressure on healthcare systems worldwide," Randy Werneth, President and Chief Executive Officer stated. "Completion of this round of financing provides us with the opportunity to expand our product portfolio in many ways and continue to innovate and validate our core product, the AcQMap System."
About Acutus Medical
Since June, 2011, Acutus Medical has pioneered a new and novel approach in the minimally invasive imaging and mapping of cardiac arrhythmias.
Acutus Medical has concentrated its efforts on developing its technology for the treatment of atrial fibrillation (AF). AF is an uncontrollable, rapid, heartbeat that results in a significant decline in the quality of life and may lead to serious complications such as stroke or heart failure. Globally, in excess of 10 million people are afflicted with AF. Pharmacological therapy is the most common current treatment option, but it is expensive, often inadequate, palliative in nature, and does not cure AF.
Acutus Medical believes that its technology may eventually play a significant role in improving the lives of countless individuals who are afflicted by AF.
Acutus Medical is a privately held company located in San Diego, CA. You can learn more about the company at www.acutusmedical.com.
This press release includes forward-looking statements regarding Acutus Medical Cardiac Imaging and Mapping Technology System and additional product lines. Any statement describing Acutus Medical's goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Acutus Medical goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing products and in the endeavor of building a business around such products. Acutus Medical's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Acutus Medical forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Acutus Medical. As a result, you are cautioned not to rely on these forward-looking statements.
For More Information, please contact:
Acutus Medical
Mr. Randy Werneth
CEO / President
(858) 673-1621
Logo - http://photos.prnewswire.com/prnh/20130430/LA01948LOGO
SOURCE Acutus Medical, Inc.